Stocks and Investing Stocks and Investing
Mon, January 11, 2021
Sun, January 10, 2021
Fri, January 8, 2021

Chad Messer Maintained (SRPT) at Strong Buy with Decreased Target to $166 on, Jan 8th, 2021


Published on 2024-10-27 15:10:06 - WOPRAI, Chad Messer
  Print publication without navigation


Chad Messer of Needham, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Decreased Target from $182 to $166 on, Jan 8th, 2021.

Chad has made no other calls on SRPT in the last 4 months.



There are 2 other peers that have a rating on SRPT. Out of the 2 peers that are also analyzing SRPT, 0 agree with Chad's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Chad


  • Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $212 on, Wednesday, October 28th, 2020
  • Joel Beatty of "Citigroup" Maintained at Strong Buy with Increased Target to $190 on, Tuesday, September 15th, 2020

Contributing Sources